Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 55 - Any |
| Updated: | 6/8/2017 |
| Start Date: | September 1998 |
| End Date: | December 2016 |
Tangential Radiation Therapy Without Axillary Dissection in Early-Stage Breast Cancer
The purpose of this study is to evaluate whether treatment to the axilla (area under the
arm) can be safely minimized by omitting axillary surgery and full axillary radiation
therapy and replacing it with radiation therapy to the breast and lower axilla.
arm) can be safely minimized by omitting axillary surgery and full axillary radiation
therapy and replacing it with radiation therapy to the breast and lower axilla.
- Patients will have undergone conservative breast surgery without axillary dissection
prior to enrollment in this study.
- Patients will receive radiation therapy to the breast, including the lowest axillary
lymph nodes, over a period of 6 1/2 weeks.
- No radiation will be specifically directed toward the upper axilla or supraclavicular
lymph nodes.
- Patients will also receive 5 years of tamoxifen or another type of hormone therapy
determined by the medical oncologist.
- Follow-up visits will occur every 6 months and mammograms every 12 months.
prior to enrollment in this study.
- Patients will receive radiation therapy to the breast, including the lowest axillary
lymph nodes, over a period of 6 1/2 weeks.
- No radiation will be specifically directed toward the upper axilla or supraclavicular
lymph nodes.
- Patients will also receive 5 years of tamoxifen or another type of hormone therapy
determined by the medical oncologist.
- Follow-up visits will occur every 6 months and mammograms every 12 months.
Inclusion Criteria:
- Patients must have clinical stage I or II breast cancer, clinically uninvolved
axillary nodes.
- Patients must be 55 years or older.
- Patients must undergo total excision of the primary invasive tumor
- Final pathologic margin status must be negative
- Only estrogen receptor (ER) or progesterone receptor (PR) positive tumors will be
permitted
Exclusion Criteria:
- Prior history of malignancy, except for non-melanoma skin cancers and carcinoma in
situ fo the cervix
We found this trial at
2
sites
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Click here to add this to my saved trials